Kavita Mishra, M.D., M.P.H.
Dr. Kavita K. Mishra is an internationally renowned expert radiation oncologist focused on the treatment of uveal melanomas with proton beam radiotherapy as well as plaque brachytherapy. She earned her undergraduate degree in Biology at Harvard University, followed by her medical degree at the UCSF School of Medicine. She then completed a masters degree at the Harvard School of Public Health. Dr. Mishra finished her residency in radiation oncology at the UCSF Medical Center and thereafter joined the faculty at UCSF.
Dr. Mishra specializes in the use of proton beam radiation and plaque brachytherapy to treat malignant and benign conditions of the eye. Dr. Mishra believes in a multidisciplinary approach to ocular oncology care with the aim to provide the most efficacious and individualized therapy for her patients. She is active in the national and international ocular oncology community, is the Co-Chair of PTCOG Ocular (Particle Therapy Co-Operative Group) - the largest collection of proton beam ocular radiation therapy institutions, and has multiple significant research publications and oral presentations globally in her areas of expertise.
Her current research protocols are focused on the clinical outcomes of uveal melanoma patients, particularly with respect to tumor control, preservation of the eye, and quality of life issues. She hopes to continue using a unified, team-oriented approach to maintain excellent outcomes for patients undergoing modern proton beam, plaque therapy, and external beam radiation techniques for ocular malignancies.
Harvard University, Cambridge, MA
University of California, San Francisco
Harvard School of Public Health, Boston
Cambridge Hospital, Cambridge, MA
University of California, San Francisco
|2015 - present||UCSF||Associate Professor|
Awards & Honors
|1997||Appointed Student Adviser to the Dean of Harvard College|
|1998||Dean’s List, Harvard University|
|1998||Elizabeth Cary Agassiz Certificate of Merit, Radcliffe College|
|1998||Harvard College Scholar, Harvard University|
|1998||First Class Marshal (Class President), Harvard Class of 1998|
|1999||Rainer Scholarship for International Health Research, UCSF|
|2002||Class Speaker, UCSF School of Medicine Commencement|
|2006-2007||Chief Resident in Radiation Oncology, UCSF|
|2008||RSNA Roentgen Resident/Fellow Research Award|
|2015||Highest ranked scientific abstract, PTCOG 2015|
Mishra KK, Daftari IK, Weinberg V, Cole T, Quivey JM, Castro JR, Phillips TL, Char DH. Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters. Int J Radiat Oncol Biol Phys. 2013 Oct 1; 87(2):330-6. PMID: 23886415
Seider MI, Stewart PJ, Mishra KK, Damato BE. Uveal melanoma gene expression profile test result provided for uveal metastasis. Ophthalmic Surg Lasers Imaging Retina. 2014 Sep 1; 45(5):441-2. PMID: 25153656.
Mishra KK, Quivey JM, Daftari IK, Weinberg V, Castro JR, Phillips TL, Char DH. In Reply to Kamrava and McCannel. Int J Radiat Oncol Biol Phys. 2015 Sep 1; 93(1):216-7. PMID: 26279045
Mishra KK, Quivey JM, Daftari IK, Weinberg V, Cole TB, Patel K, Castro JR, Phillips TL, Char DH. Long-term Results of the UCSF-LBNL Randomized Trial: Charged Particle With Helium Ion Versus Iodine-125 Plaque Therapy for Choroidal and Ciliary Body Melanoma. Int J Radiat Oncol Biol Phys. 2015 Jun 1; 92(2):376-83. PMID: 25841624
Mishra KK, Polishchuk AL, Weinberg V, Daftari IK, Nguyen JM, Cole TB, Quivey JM, Phillips TL, Char DH. Temporal Evolution and Dose-Volume Histogram Predictors of Visual Acuity After Proton Beam Radiation Therapy of Uveal Melanoma. Int J Radiat Oncol Biol Phys. 2016 Sep 23. PMID: 27838186.
Roach MR, Schulte R, Mishra KK, Faddegon B, Barani I, Lazar A, Blakely EA. New Clinical and research programs in particle beam radiation - The UCSF perspective. Int J Part Ther. 2016 Winter; 2(3): 471-473. (doi: http://dx.doi.org/10.14338/IJPT-15-00025.1)
Daftari IK, Mishra KK, Singh RP, Shadoan DJ, Phillips TL. An overview of the control system for dose delivery at the UCSF dedicated ocular proton beam. Int J Med Phys Clin Eng Radiat Oncol. 2016; 5:242-262.
Hrbacek J, Mishra KK, Kacperek A, Dendale R, Nauraye C, Auger M, Herault J, Daftari IK, Trofimov AV, Shih HA, Chen YL, Denker A, Heufelder J, Horwacik T, Swakon J, Hoehr C, Duzenli C, Pica A, Goudjil F, Mazal A, Thariat J, Weber DC. Practice Patterns Analysis of Ocular Proton Therapy Centers: The International OPTIC Survey. Int J Radiat Oncol Biol Phys. 2016 May 1; 95(1):336-43. PMID: 27084651
Mishra KK. Particle therapy is ideal for the treatment of ocular melanomas. Med Phys. 2016 Feb; 43(2):631-634. PMID: 26843226
Mishra KK, Daftari IK. Proton therapy for the management of uveal melanoma and other ocular tumors. Chin Clin Oncol. 2016 Aug; 5(4):50-56. PMID: 27558251. doi: 10.21037/cco.2016.07.06
Osmanovic S, Moisseiev, E, Mishra KK, Daftari IK, Moshiri A, Morse L, Park SS. Phase I/II randomized study of proton beam with anti-VEGF for exudative age-related macular degeneration: One-year results. Ophthal Retina. 2017; 1:217-226.
Daftari IK, Quivey J, Chang J, Mishra KK. Feasibility study of titanium markers in choroidal melanoma localization for proton beam radiation therapy. Medical Physics (accepted).
Haas-Kogan D, Indelicato D, Paganetti H, Esiashvili N, Mahajan A, Yock T, Flampouri S, MacDonald S, Fouladi M, Kry S, Kalapurakal J, Terezakis S, Kooy H, Grosshans D, Makrigiorgos M, Mishra KK, et al. NCI Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. Int J Radiat Oncol Biol Phys.